Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies

Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

28-Aug-2023 - Switzerland
Computer-generated image

Symbolic image

Mysthera Therapeutics AG, a company developing first-in-class, oral therapeutics to treat complex autoimmune diseases, launched with $3.5 million seed capital from founding investor Forty51 Ventures. The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions.

PIM kinases are gateway kinases in multiple immune cell lineages (including B and T effector cells) driving excessive inflammation. Elevated PIM kinase may further contribute to the formation and maintenance of tertiary lymphoid structures (TLS) which are associated with disease severity and progression.

Autoimmune diseases impact over 23 million in US alone. Despite recent progress and novel treatment options, significant unmet needs remain due to poor response rates and adverse safety profiles of currently available treatment medicines.

Mysthera’s founding management team and board of directors brings considerable experience, leadership and a successful track record across research and development.

“Leveraging our deep expertise in PIM kinase and immunology, we are pursuing a highly differentiated approach to tackle complex autoimmune diseases. We believe this will result in new treatments to change the lives of patients globally”, said Darren Cunningham, co-Founder and Chief Executive Officer at Mysthera Therapeutics.

“PIM inhibition most critically hits effector B and T cells at the site of inflammation and inhibits their activation” added Dr. Stefan Haak, co-Founder and SVP R&D at Mysthera Therapeutics. “Our approach is uniquely positioned to also silence the essential cross-talk between these cells, impeding the pathogenic TLS formation associated with more erosive disease.”

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.